Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Eliza Kramer to Cystic Fibrosis

This is a "connection" page, showing publications Eliza Kramer has written about Cystic Fibrosis.

 
Connection Strength
 
 
 
3.008
 
  1. Scharf G, Davidson CR, Ustiyan V, Falkenberg LG, Adavalli A, Meeker JD, Morgan H, Ostmann AJ, Hudock KM, Brewington JJ, Clancy JP, Kramer EL. TGF-ß induces excessive pulmonary IL-6 secretion in cystic fibrosis via PI3K. Am J Physiol Lung Cell Mol Physiol. 2025 10 01; 329(4):L470-L479.
    View in: PubMed
    Score: 0.446
  2. Kramer EL, Hudock KM, Davidson CR, Clancy JP. CFTR dysfunction in smooth muscle drives TGFß dependent airway hyperreactivity. Respir Res. 2023 Aug 11; 24(1):198.
    View in: PubMed
    Score: 0.386
  3. Kramer EL, Madala SK, Hudock KM, Davidson C, Clancy JP. Subacute TGFß Exposure Drives Airway Hyperresponsiveness in Cystic Fibrosis Mice through the PI3K Pathway. Am J Respir Cell Mol Biol. 2020 05; 62(5):657-667.
    View in: PubMed
    Score: 0.308
  4. Kramer EL, Hardie WD, Madala SK, Davidson C, Clancy JP. Subacute TGFß expression drives inflammation, goblet cell hyperplasia, and pulmonary function abnormalities in mice with effects dependent on CFTR function. Am J Physiol Lung Cell Mol Physiol. 2018 09 01; 315(3):L456-L465.
    View in: PubMed
    Score: 0.270
  5. Kramer EL, Clancy JP. MicroRNA-145, Cystic Fibrosis Transmembrane Conductance Regulator, and Transforming Growth Factor-ß. An (Un)tangled Regulatory Web. Am J Respir Crit Care Med. 2018 03 01; 197(5):551-552.
    View in: PubMed
    Score: 0.265
  6. Kramer EL, Clancy JP. TGFß as a therapeutic target in cystic fibrosis. Expert Opin Ther Targets. 2018 02; 22(2):177-189.
    View in: PubMed
    Score: 0.261
  7. Matheson AM, Prather E, Willmering MM, Mata J, Santyr G, Ratjen FA, Kramer EL, Cleveland ZI, Woods JC. Lung mucus burden and treatment response assessed by MRI in the post-modulator era. J Cyst Fibros. 2026 Jul; 25(4):711-717.
    View in: PubMed
    Score: 0.117
  8. Matheson AM, Bdaiwi AS, Willmering MM, DiFrancesco MW, Cleveland ZI, Santyr GE, Ratjen F, Kramer EL, Szczesniak RD, Woods JC. Structural and Functional Pulmonary MRI to Predict Pulmonary Exacerbations in Cystic Fibrosis. Chest. 2026 Apr; 169(4):919-931.
    View in: PubMed
    Score: 0.113
  9. Hussain R, Plummer JW, Bdaiwi AS, Willmering MM, Kramer EL, Walkup LL, Cleveland ZI. Optimizing Xenon 129 Ventilation MRI in Cystic Fibrosis with Spiral Imaging and Flip-Angle Correction. Radiol Cardiothorac Imaging. 2025 10; 7(5):e240574.
    View in: PubMed
    Score: 0.112
  10. Cheng Y, Brokamp C, Manning ER, Kramer EL, Ryan PH, Szczesniak RD, Gecili E. Hypercubes to identify geomarkers of rapid cystic fibrosis lung disease progression. BMC Med Inform Decis Mak. 2025 08 13; 25(1):304.
    View in: PubMed
    Score: 0.111
  11. Bdaiwi AS, Roach DJ, West ME, Willmering MM, Daou AW, Hossain MM, Kramer EL, Amin R, Walkup LL, Cleveland ZI, Woods JC. Longitudinal Monitoring of Lumacaftor/Ivacaftor Response in Young Children with Cystic Fibrosis Lung Disease Using 129Xe MRI. Acad Radiol. 2025 Oct; 32(10):6238-6249.
    View in: PubMed
    Score: 0.110
  12. Bdaiwi AS, Svoboda AM, Murdock KE, Hendricks A, Hossain MM, Kramer EL, Brewington JJ, Willmering MM, Woods JC, Walkup LL, Cleveland ZI. Quantifying abnormal alveolar microstructure in cystic fibrosis lung disease via hyperpolarized 129Xe diffusion MRI. J Cyst Fibros. 2024 09; 23(5):926-935.
    View in: PubMed
    Score: 0.103
  13. Willmering MM, Roach DJ, Kramer EL, Walkup LL, Cleveland ZI, Woods JC. Sensitive structural and functional measurements and 1-year pulmonary outcomes in pediatric cystic fibrosis. J Cyst Fibros. 2021 05; 20(3):533-539.
    View in: PubMed
    Score: 0.080
  14. Gardner AI, Haq IJ, Simpson AJ, Becker KA, Gallagher J, Saint-Criq V, Verdon B, Mavin E, Trigg A, Gray MA, Koulman A, McDonnell MJ, Fisher AJ, Kramer EL, Clancy JP, Ward C, Schuchman EH, Gulbins E, Brodlie M. Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis. Am J Respir Crit Care Med. 2020 10 15; 202(8):1133-1145.
    View in: PubMed
    Score: 0.079
  15. Kasam RK, Gajjala PR, Jegga AG, Courtney JA, Randell SH, Kramer EL, Clancy JP, Madala SK. Fibrocyte accumulation in the lungs of cystic fibrosis patients. J Cyst Fibros. 2020 09; 19(5):815-822.
    View in: PubMed
    Score: 0.078
  16. Szczesniak RD, Pestian T, Duan LL, Li D, Stamper S, Ferrara B, Kramer E, Clancy JP, Grossoehme D. Data driven decision making to characterize clinical personas of parents of children with cystic fibrosis: a mixed methods study. BMC Pulm Med. 2020 Jun 18; 20(1):174.
    View in: PubMed
    Score: 0.078
  17. Brewington JJ, Backstrom J, Feldman A, Kramer EL, Moncivaiz JD, Ostmann AJ, Zhu X, Lu LJ, Clancy JP. Chronic ß2AR stimulation limits CFTR activation in human airway epithelia. JCI Insight. 2018 02 22; 3(4).
    View in: PubMed
    Score: 0.066
  18. Peterson CJ, Rao MB, Palipana A, Manning ER, Vancil A, Ryan P, Brokamp C, Kramer E, Szczesniak RD, Gecili E. Robust identification of environmental exposures and community characteristics predictive of rapid lung disease progression. Sci Total Environ. 2024 Nov 10; 950:175348.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)